References ORiordan, KJ, Moloney, GM, Keane, L, Clarke, G & Cryan, JF The gut microbiota-immune-brain axis: Therapeutic implications
In clinical trials, semaglutide and tirzepatide consistently lower C-reactive protein (CRP), yet only 2060% of that improvement can be explained by weight or glucose changes
Yau K, Odutayo A, Dash S, et al
30 Insights on GLP-1 GLP-1 Insight 1 Many people using GLP-1 medications are between 50 and 69 years old, which suggests that these treatments are common in middle-aged adults
Chou CC, Pan SY, Sheen YJ, Lin JF, Lin CH, Lin HJ, et al
Notably, sensitivity analysis by omitting one of the studies [22] for the subgroup with treatment durations of 6 months indicated a significantly greater WL in the GLP-1RAs group compared to placebo (SMD = 0.79